
Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 17, 2026, titled "Aurobindo Pharma receives USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension, 30 mg/5 mL (OTC)".
Filed with NSE · · 3 pages · English

Aurobindo Pharma Limited has informed the Exchange regarding a press release dated April 17, 2026, titled "Aurobindo Pharma receives USFDA approval for Dextromethorphan Polistirex Extended-Release Oral Suspension, 30 mg/5 mL (OTC)".
Follow Aurobindo Pharma into a list and get an email when it puts out news.
Follow Aurobindo Pharma